Differential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 mice

Toxicology and Applied Pharmacology

Volumn 218, Issue 3, 2007, Pages 227-237

  Auttachoat, Wimolnut ^a   Zheng, Jian Feng ^a   Chi, Rui P ^a   Meng, Andrew ^a   Guo, Tai L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adhesion molecules; Neutrophils; Thalidomide

Indexed keywords

CD18 ANTIGEN; HERMES ANTIGEN; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYELOPEROXIDASE; THALIDOMIDE;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GRANULOPOIESIS; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHILIA; NONHUMAN; SPLEEN; TISSUE DISTRIBUTION;

ANIMALS; ANTIGENS, CD18; ANTIGENS, CD44; BONE MARROW; CELL ADHESION MOLECULES; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MICE; MICE, INBRED STRAINS; NEUTROPHILS; PEROXIDASE; SPLEEN; THALIDOMIDE;

MUS;

EID: 33846621874     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.11.019     Document Type: Article

References (42)

1. Auttachoat W., Chitsomboon B., Peachee V.L., Guo T.L., and White Jr. K.L. Immunomodulation by Dok Din Daeng (Aeginetia indica Roxb.) extracts in female B6C3F1 mice: II. Humoral immunity, innate immunity and hematology. Int. Immunopharmacol. 4 (2004) 1381-1390
2. Burdon P.C., Martin C., and Rankin S.M. The CXC chemokine MIP-2 stimulates neutrophil mobilization from the rat bone marrow in a CD49d-dependent manner. Blood 105 (2005) 2543-2548
3. Cherian S., Moore J., Bantly A., Vergilio J.A., Klein P., Luger S., and Bagg A. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytom., B Clin. Cytom. 64 (2005) 9-17
4. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., Lin B., Podar K., Gupta D., Chauhan D., Treon S.P., Richardson P.G., Schlossman R.L., Morgan G.J., Muller G.W., Stirling D.I., and Anderson K.C. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 8 (2001) 210-216
5. Eriksson T., Hoglund P., Turesson I., Waage A., Don B.R., Vu J., Scheffler M., and Kaysen G.A. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J. Pharm. Pharmacol. 55 (2003) 1701-1706
6. Fuhler G.M., Drayer A.L., and Vellenga E. Decreased phosphorylation of protein kinase B (PKB/Akt) and extracellular signal-regulated kinase (ERK) in neutrophils from patients with myelodysplasia. Blood 101 (2003) 1172-1180
7. Fuhler G.M., Knol G.J., Drayer A.L., and Vellenga E. Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J. Leukocyte Biol. 77 (2005) 257-266
8. Geitz H., Handt S., and Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31 (1996) 213
9. Guo T.L., Zhang L.X., Chen J.P., Nguyen V.A., White Jr. K.L., and Gao B. Differential STAT5 activation and phenotypic marker expression by immune cells following low levels of ethanol consumption in mice. Immunopharmacol. Immunotoxicol. 24 (2002) 121
10. Guo T.L., Chi R.P., Karrow N.A., Zhang L.X., Pruett S.B., Germolec D.R., and White Jr. K.L. Thalidomide enhances both primary and secondary host resistances to Listeria monocytogenes infection by a neutrophil-related mechanism in female B6C3F1 mice. Toxicol. Appl. Pharmacol. 209 (2005) 244-254
11. Hejtmancik M.R., Ryan M.J., Toft J.D., Persing R.L., Kurtz P.J., and Chhabra R.S. Hematological effects in F344 rats and B6C3F1 mice during the 13-week gavage toxicity study of methylene blue trihydrate. Toxicol. Sci. 65 (2002) 126-134
12. Hock H., Hamblen M.J., Rooke H.M., Traver D., Bronson R.T., Cameron S., and Orkin S.H. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 18 (2003) 109-120
13. Hodgson. Toxicology testing and risk assessment. In: Hodgson E., and Levi P.E. (Eds). A Textbook of Modern Toxicology. 2nd ed. (1997), Appleton & Lange, Stamford, CT 336
14. Horwitz B.H., Mizgerd J.P., Scott M.L., and Doerschuk C.M. Mechanisms of granulocytosis in the absence of CD18. Blood 97 (2001) 1578-1583
15. Invernizzi R., Travaglino E., De Amici M., Brugnatelli S., Ramajoli I., Rovati B., Benatti C., and Ascari E. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk. Res. 29 (2005) 641-647
16. Karrow N.A., McCay J.A., Brown R.D., Musgrove D.L., Pettit D.A., Munson A.E., Germolec D.R., and White Jr. K.L. Thalidomide stimulates splenic antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol. Appl. Pharmacol. 165 (2000) 237
17. Karrow N.A., Guo T.L., Zhang L.X., McCay J.A., Musgrove D.L., Peachee V.L., Germolec D.R., and White Jr. K.L. Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study. Int. Immunopharmacol. 3 (2003) 1447
18. Kouides P.A., and Bennett J.M. Understanding the myelodysplastic syndromes. Oncologist 2 (1997) 389-401
19. Leckie M.J., Bryan S.A., Khan J., Dewar A., Aikman S.L., McGrath J., Okrongly D.A., Burman J.F., Barnes P.J., and Hansel T.T. Automated quantitation of circulating neutrophil and eosinophil activation in asthmatic patients. Thorax 55 (2000) 471-477
20. Lin Y.W., Slape C., Zhang Z., and Aplan P.D. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 106 (2005) 287-295
21. Lubbert M., Daskalakis M., Kunzmann R., Engelhardt M., Guo Y., and Wijermans P. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2′-deoxycytidine (decitabine). Leuk. Res. 28 (2004) 1267-1271
22. Lyden S.P., Patton Jr. J.H., Ragsdale D.N., Croce M.A., Fabian T.C., and Proctor K.G. Transient inhibition of CD18-dependent leukocyte functions after hemorrhage and polymicrobial sepsis. Surgery 123 (1998) 679-691
23. Marriott J.B., Muller G., and Dalgleish A.G. Thalidomide as an emerging immuno-therapeutic agent. Immunol. Today 20 (1999) 538
24. Mazzone A., Porta C., Fossati G., Gritti D., Mazzucchelli I., and Ricevuti G. Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. Leuk. Lymphoma 23 (1996) 267-275
25. Miyamoto M., Emoto M., Emoto Y., Brinkmann V., Yoshizawa I., Seiler P., Aichele P., Kita E., and Kaufmann S.H. Neutrophilia in LFA-1-deficient mice confers resistance to listeriosis: possible contribution of granulocyte-colony-stimulating factor and IL-17. J. Immunol. 170 (2003) 5228
26. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., and Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 59 (1985) 425-433
27. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk. Res. 28 (2004) 325-332
28. Nakagawa M., Terashima T., D'yachkova Y., Bondy G.P., Hogg J.C., and van Eeden S.F. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 98 (1998) 2307-2313
29. Nelson D.A. The biology of myelopoiesis. Clin. Lab. Med. 10 (1990) 649-659
30. Nogueira A.C., Neubert R., Helge H., and Neubert D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci. 55 (1994) 77
31. Ohsaka A., Saionji K., Igari J., Watanabe N., Iwabuchi K., and Nagaoka I. Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br. J. Haematol. 98 (1997) 108-113
32. Pericle F., Sconocchia G., Titus J.A., and Segal D.M. CD44 is a cytotoxic triggering molecule on human polymorphonuclear cells. J. Immunol. 157 (1996) 4657-4663
33. Raza A., Buonamici S., Lisak L., Tahir S., Li D., Imran M., Chaudary N.I., Pervaiz H., Gallegos J.A., Alvi M.I., Mumtaz M., Gezer S., Venugopal P., Reddy P., Galili N., Candoni A., Singer J., and Nucifora G. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk. Res. 28 (2004) 791-803
34. Sato Y., Walley K.R., Klut M.E., English D., D'yachkova Y., Hogg J.C., and van Eeden S.F. Nitric oxide reduces the sequestration of polymorphonuclear leukocytes in lung by changing deformability and CD18 expression. Am. J. Respir. Crit. Care Med. 159 (1999) 1469-1476
35. Shikama Y., Shichishima T., Matsuoka I., Jubinsky P.T., Sieff C.A., and Maruyama Y. Accumulation of an intron-retained mRNA for granulocyte macrophage-colony stimulating factor receptor common beta chain in neutrophils of myelodysplastic syndromes. J. Leukocyte Biol. 77 (2005) 811-819
36. Stetler-Stevenson M., Arthur D.C., Jabbour N., Xie X.Y., Molldrem J., Barrett A.J., Venzon D., and Rick M.E. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98 (2001) 979-987
37. Tohnya T.M., Hwang K., Lepper E.R., Fine H.A., Dahut W.L., Venitz J., Sparreboom A., and Figg W.D. Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 811 (2004) 135-141
38. Wang Q., Teder P., Judd N.P., Noble P.W., and Doerschuk C.M. CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am. J. Pathol. 161 (2002) 2219-2228
39. Weiss D.J., and Evanson O.A. Evaluation of activated neutrophils in the blood of horses with colic. Am. J. Vet. Res. 64 (2003) 1364-1368
40. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., and Deeg H.J. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102 (2003) 394-403
41. Zhang P., Quinton L.J., Gamble L., Bagby G.J., Summer W.R., and Nelson S. The granulopoietic cytokine response and enhancement of granulopoiesis in mice during endotoxemia. Shock 23 (2005) 344-352
42. Zwingenberger K., and Wnendt S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflammation 46 (1995) 177